

CHEMICAL HERITAGE FOUNDATION

JOHN D. ALTMAN

The Pew Scholars Program in the Biomedical Sciences

Transcript of an Interview
Conducted by

Karen A. Frenkel

at

Emory Vaccine Center in the Yerkes Regional Primate Center, Emory University
Atlanta, Georgia

on

30 and 31 January and 1 February 2006

From the Original Collection of the University of California, Los Angeles

ACKNOWLEDGEMENT

This oral history is part of a series supported by a grant from the Pew Charitable Trusts based on the Pew Scholars Program in the Biomedical Sciences. This collection is an important resource for the history of biomedicine, recording the life and careers of young, distinguished biomedical scientists and of Pew Biomedical Scholar Advisory Committee members.

This oral history was completed under the auspices of the Oral History Project, University of California, Los Angeles (Copyright © 2007, The Regents of the University of California) and is made possible through the generosity of



**From the original collection at the Center for
Oral History Research, UCLA Library, UCLA.**

The following oral history, originally processed at the UCLA Center for Oral History Research, has been reformatted by the Chemical Heritage Foundation. The process involved reformatting the front matter, adding a new abstract, replacing the table of contents, and replacing the index. The paragraph spacing and font of the body of the transcript were altered to conform to the standards of the Oral History Program at the Chemical Heritage Foundation. The text of the oral history remains unaltered; any inadvertent spelling or factual errors in the original manuscript have not been modified. The reformatted version and digital copies of the interview recordings are housed at the Othmer Library, Chemical Heritage Foundation. The original version and research materials remain at the Darling Library, University of California, Los Angeles and at the Bancroft Library, University of California, Berkeley.

REFORMATTING:

Kim Phan, Program Intern, Oral History, Chemical Heritage Foundation. B.A. expected 2011, Anthropology, Cornell University.

David J. Caruso, Program Manager, Oral History, Chemical Heritage Foundation. B.A., History of Science, Medicine, and Technology, Johns Hopkins University; PhD., Science and Technology Studies, Cornell University.



In exchange for the UCLA Oral History Program conducting and recording the series of interviews with me beginning on or about January 31, 2006, I, John D. Altman, do hereby give all right, title, and interest, including copyright, in and to those interviews to the Regents of the University of California to be used for any research, educational, or other purpose that the University may deem appropriate. I understand that I may still use the information in the recordings myself without seeking permission from the University.

I have read and agree to the UCLA Oral History Program's Use Policy, which outlines the current and likely future uses of interviews donated to the Oral History Program's collection.

Unless otherwise specified below, I place no restrictions on access to and use of the interviews.

A handwritten signature of John D. Altman.

Interviewee (Signature)

John D. Altman

(Typed Name)

Emory University

(Address)

(494)727-5981

(Phone Number)

altman@microbiobio.edu

(E-mail Address)

January 17, 2006

(Date)

Signed on behalf of the Regents of the University of California:

A handwritten signature of Teresa Barnett.

Head, UCLA Oral History Program

Teresa Barnett

(Typed Name)

(310) 206-2454

(Phone Number)

tbartnett@library.ucla.edu

(E-mail Address)

2/6/06

(Date)

This interview has been designated as **Free Access**.

One may view, quote from, cite, or reproduce the oral history with the permission of CHF.

Please note: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to credit CHF using the format below:

John D. Altman, interview by Karen A. Frenkel at the Emory Vaccine Center in the Yerkes Regional Primate Center, Emory University, Atlanta, Georgia, 30-31 January and 1 February 2006 (Philadelphia: Chemical Heritage Foundation, Oral History Transcript # 0476).



Chemical Heritage Foundation
Oral History Program
315 Chestnut Street
Philadelphia, Pennsylvania 19106



The Chemical Heritage Foundation (CHF) serves the community of the chemical and molecular sciences, and the wider public, by treasuring the past, educating the present, and inspiring the future. CHF maintains a world-class collection of materials that document the history and heritage of the chemical and molecular sciences, technologies, and industries; encourages research in CHF collections; and carries out a program of outreach and interpretation in order to advance an understanding of the role of the chemical and molecular sciences, technologies, and industries in shaping society.

JOHN D. ALTMAN

1962 Born in Detroit, Michigan, on 6 October

Education

1984 S.B., Chemistry, Massachusetts Institute of Technology
1991 Ph.D., Pharmaceutical Chemistry, University of California,
San Francisco

Professional Experience

Stanford University
1991-1996 Postdoctoral Fellow, with Dr. Mark Davis

Emory University
1997-present Associate Professor of Microbiology and Immunology,
School of Medicine
1997-present Affiliate Scientist, Yerkes Regional Primate Center of
Emory University
1997-present Affiliate Scientist, Emory Vaccine Center
1998-present Director, Emory Vaccine Center Flow Cytometry Facility
2001 Interim Director, Emory University School of Medicine Flow
Cytometry Core Facility

Honors

1980 University of Michigan Regents Scholarship
1984 American Institute of Chemists Student Award
1984 Phi Beta Kappa, MIT
1984-1987 National Science Foundation Graduate Fellow
1987-1988 University of California Regents Fellow
1991-1994 Postdoctoral Fellow of the American Cancer Society
1999-2003 Pew Scholar in the Biomedical Sciences

Selected Publications

Crespi, C. L., Altman, J. D. & Marletta, M. A. (1985). "Xenobiotic metabolism and mutation in a human lymphoblastoid cell line." *Chem. Biol. Interact.*, 53, 257-71.

- Collins, S., Altman, J. D. & Marletta, M. A. (1985). "Development of an affinity chromatography resin for the purification of carcinogen binding proteins from mouse liver." *Biochem. Biophys. Res. Commun.*, 129, 155-62.
- Altman, J., Lipka, J. J., Kuntz, I. & Waskell, L. (1989). "Identification by proton nuclear magnetic resonance of the histidines in cytochrome b5 modified by diethyl pyrocarbonate." *Biochemistry*, 28, 75 16-23.
- Guiles, R. D., Altman, J., Kuntz, I. D., Waskell, L. & Lipka, J. J. (1990). "Structural studies of cytochrome b5: complete sequence-specific resonance assignments for the trypsin-solubilized microsomal ferrocyanocytchrome b5 obtained from pig and calf." *Biochemistry*, 29, 1276-89.
- Altman, J. D., Henner, D., Nilsson, B., Anderson, S. & Kuntz, I. D. (1991). "Intracellular expression of BPTI fusion proteins and single column cleavage/affinity purification by chymotrypsin." *Protein Engin.*, 4, 593-600.
- Driscoll, P. C., Altman, J. D., Boniface, J. J., Sakaguchi, K., Reay, P. A., Omichinski, J. G., Appella, E. & Davis, M. M. (1993). "Two-dimensional nuclear magnetic resonance analysis of a labeled peptide bound to a class II major histocompatibility complex molecule." *J. Mol. Biol.*, 232, 342-50.
- Altman, J. D., Reay, P. A. & Davis, M. M. (1993). "Formation of functional peptide complexes of class II major histocompatibility complex proteins from subunits produced in Escherichia coli." *Proc. Natl. Acad. Sci. U.S.A.*, 90, 10330-4.
- Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J. & Davis, M. M. (1996). "Phenotypic analysis of antigen-specific T lymphocytes." *Science*, 274, 94-96.
- Reich, Z., Altman, J. D., Boniface, J. J., Lyons, D. S., Kozono, H., Ogg, G., Morgan, C. & Davis, M. M. (1997). "Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins." *Proc. Natl. Acad. Sci. U. S. A.*, 94, 2495-500.
- Crowley, M. P., Reich, Z., Mavaddat, N., Altman, J. D. & Chien, Y. (1997). "The recognition of the nonclassical major histocompatibility complex (MHC) class I molecule, T10, by the gammadelta T cell, G8." *J. Exp. Med.*, 185, 1223-30.
- Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J. & Ahmed, R. (1998). "Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection." *Immunity*, 8, 177-187.
- Flynn, K. J., Belz, G. T., Altman, J. D., Ahmed, R., Woodland, D. L. & Doherty, P. C. (1998). "Virus-specific CD8⁺ T cells in primary and secondary influenza pneumonia." *Immunity*, 8, 683-691.
- Bousso, P., Casrouge, A., Altman, J. D., Haury, M., Kanelopoulos, J., Abastado, J.-P. & Kourilsky, P. (1998). "Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires." *Immunity*, 9, 169-178.
- Sourdive, D. J. D., Murali-Krishna, K., Altman, J. D., Zajac, A. J., Whitmire, J., Pannetier, C., Kourilsky, P., Evavold, B., Sette, A. & Ahmed, R. (1998). "Conserved TCR repertoire in primary and memory CD8 T cell responses to an acute viral infection." *J. Exp. Med.*, 188, 71-82.
- Boniface, J. J., Rabinowitz, J. D., Wülfing, C., Hampl, J., Reich, Z., Altman, J. D., Kantor, R. M., Beeson, C., McConnell, H. M. & Davis, M. M. (1998). "Initiation of Signal Transduction through the T Cell Receptor Requires the Peptide Multivalent Engagement of MHC Ligands."

Immunity, 9, 459-466.

- Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J., Suresh, M., Altman, J. D. & Ahmed, R. (1998). "Viral Immune Evasion due to Persistence of Activated T-Cells Without Effector Function." *J. Exp. Med.*, 188, 2205-2213.
- Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E. & Raulet, D. H. (1998). "Mouse CD94/NKG2A is a Natural Killer Cell Receptor for Qa-1^b, a Nonclassical MHC Class I Molecule." *J. Exp. Med.*, 188, 1841-8.
- Gutgemann, I., Fahrer, A. M., Altman, J. D., Davis, M. M. & Chien, Y. H. (1998). "Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen." *Immunity*, 8, 667-73.
- Belz, G. T., Altman, J. D. & Doherty, P. C. (1998). "Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia." *Proc. Natl. Acad. Sci. U.S.A.*, 95, 13812-7.
- Stevenson, P. G., Belz, G. T., Altman, J. D. & Doherty, P. C. (1998). "Virus-specific CD8(+) T cell numbers are maintained during gamma-herpesvirus reactivation in CD4-deficient mice." *Proc. Natl. Acad. Sci. U.S.A.*, 95, 15565-70.
- Bieganowska, K., Höllsbert, P., Buckle, G. J., Lim, D.-G., Greften, J., Schneck, J., Altman, J. D., Jacobson, S., Ledis, S. L., Hanchard, B., Chin, J., Morgan, O., Roth, P. A. & Hafler, D. A. (1998). "Direct analysis of viral-specific CD8⁺ T-cells with soluble HLA-A2/Tax1 1-19 tetramer complexes in patients with HTLV-I-associated myelopathy." *J. Immunol.*, 162, 1765-1771.
- Riberdy, J. M., Flynn, K. J., Stech, J., Webster, R. G., Altman, J. D. & Doherty, P. C. (1999). "Protection against a lethal avian influenza A virus in a mammalian system." *J. Virol.*, 73, 1453-9.
- Stevenson, P. G., Belz, G. T., Altman, J. D. & Doherty, P. C. (1999). "Changing patterns of dominance in the CD8+ T cell response during acute and persistent murine gammaherpesvirus infection." *Eur. J. Immunol.*, 29, 105 9-67.
- Gray, C. M., Lawrence, J., Schapiro, J. M., Altman, J. D., Winters, M. A., Crompton, M., Loi, M., Kundu, S. K., Davis, M. M. & Merigan, T. C. (1999). "Frequency of Class I HLA Restricted Anti-HIV CD8+ T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART)." *J. Immunol.*, 162, 1780-1788.
- Cousens, L. P., Peterson, R., Hsu, S., Dorner, A., Altman, J. D., Ahmed, R. & Biron, C. A. (1999). "Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection." *J. Exp. Med.*, 189, 1315-28.
- Wilson, C. S., Moser, J. M., Altman, J. D., Jensen, P. E. & Lukacher, A. E. (1999). "Cross-recognition of two middle T protein epitopes by immunodominant polyoma virus-specific CTL." *J. Immunol.*, 162, 3933-41.
- Flynn, K. J., Riberdy, J. M., Christensen, J. P., Altman, J. D. & Doherty, P. C. (1999). "In vivo proliferation of naive and memory influenza specific CD8(+) T cells." *Proc. Natl. Acad. Sci. U.S.A.*, 96, 8597-602.
- Baldwin, K. K., Trenchak, B. P., Altman, J. D. & Davis, M. M. (1999). "Negative selection of T cells occurs throughout thymic development." *J. Immunol.*, 163, 689-98.
- Hanke, T., Takizawa, H., McMahon, C. W., Busch, D. H., Pamer, E. G., Miller, J. D., Altman, J. D., Liu, Y., Cado, D., Lemonnier, F. A., Bjorkman, P. J. & Raulet, D. H. (1999). "Direct

- assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors.” *Immunity*, 11, 67-77.
- Usherwood, E. J., Hogan, R. J., Crowther, G., Surman, S. L., Hogg, T. L., Altman, J. D. & Woodland, D. L. (1999). “Functionally heterogeneous CD8(+) T-cell memory is induced by Sendai virus infection of mice.” *J. Virol.*, 73, 7278-86.
- Lukacher, A. E., Moser, J. M., Hadley, A. & Altman, J. D. (1999). “Visualization of polyoma virus-specific CD8+ T cells in vivo during infection and tumor rejection.” *J. Immunol.*, 163, 3369-78.
- Bergmann, C. C., Altman, J. D., Hinton, D. & Stohlman, S. A. (1999). “Inverted immunodominance and impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system.” *J. Immunol.*, 163, 3 379-87.
- Zajac, A. J., Vance, R. E., Held, W., Sourdice, D. J., Altman, J. D., Raulet, D. H. & Ahmed, R. (1999). “Impaired anti-viral T cell responses due to expression of the LY49A inhibitory receptor.” *J. Immunol.*, 163, 5526-34.
- Puglielli, M. T., Browning, J. L., Brewer, A. W., Schreiber, R. D., Shieh, W. J., Altman, J. D., Oldstone, M. B., Zaki, S. R. & Ahmed, R. (1999). “Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway.” *Nat. Med.*, 5, 1370-1374.
- Murali-Krishna, K., Lau, L. L., Sambhara, S., Lemonnier, F., Altman, J. & Ahmed, R. (1999). “Persistence of Memory CD8 T Cells in MHC Class I-Deficient Mice.” *Science*, 286, 1377-1381.
- Stevenson, P. G., Belz, G. T., Castrucci, M. R., Altman, J. D. & Doherty, P. C. (1999). “A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.” *Proc. Natl. Acad. Sci. U.S.A.*, 96, 928 1-6.
- Lefrancois, L., Altman, J. D., Williams, K. & Olson, S. (2000). “Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.” *J. Immunol.*, 164, 725-32.
- Whitmire, J. K., Murali-Krishna, K., Altman, J. & Ahmed, R. (2000). “Antiviral CD4 and CD8 T-cell memory: differences in the size of the response and activation requirements.” *Philos. Trans. R. Soc. Lond. B Biol. Sci.*, 355, 373-9.
- Belz, G. T., Stevenson, P. G., Castrucci, M. R., Altman, J. D. & Doherty, P. C. (2000). “Postexposure vaccination massively increases the prevalence of gamma - herpesvirus-specific CD8+ T cells but confers minimal survival advantage on CD4-deficient mice.” *Proc. Natl. Acad. Sci. U. S. A.*, 97, 2725-30.
- Harrington, L. E., Galvan, M., Baum, L. G., Altman, J. D. & Ahmed, R. (2000). “Differentiating between Memory and Effector CD8 T Cells by Altered Expression of Cell Surface O-Glycans.” *J. Exp. Med.*, 191, 1241-1246.
- Grayson, J. M., Zajac, A. J., Altman, J. D. & Ahmed, R. (2000). “Cutting Edge: Increased Expression of Bcl-2 in Antigen-Specific Memory CD8+ T Cells.” *J. Immunol.*, 164, 3950-3954.
- Belz, G. T., Xie, W., Altman, J. D. & Doherty, P. C. (2000). “A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge.” *J. Virol.*, 74, 3486-93.
- Bosselut, R., Kubo, S., Guinter, T., Kopacz, J. L., Altman, J. D., Feigenbaum, L. &

- Singer, A. (2000). "Role of CD8beta domains in CD8 coreceptor function: importance for MHC I binding, signaling, and positive selection of CD8+ T cells in the thymus ." *Immunity*, 12, 409-18.
- Blattman, J. N., Sourdive, D. J. D., Murali-Krishna, K., Ahmed, R. & Altman, J. D. (2000). "Evolution of the T Cell Repertoire During Primary, Memory, and Recall Responses to Viral Infection." *J. Immunol.*, 165, 608 1-6090.
- Kuklin, N. A., Rott, L., Darling, J., Campbell, J. J., Franco, M., Feng, N., Muller, W., Wagner, N., Altman, J., Butcher, E. C. & Greenberg, H. B. (2000). " $\alpha(4)\beta(7)$ independent pathway for CD8(+) T cell-mediated intestinal immunity to rotavirus." *J Clin Invest*, 106, 1541-52
- Cromwell, M. A., Veazey, R. S., Altman, J. D., Mansfield, K. G., Glickman, R., Allen, T. M., Watkins, D. I., Lackner, A. A. & Johnson, R. P. (2000). "Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus." *J. Virol.*, 74, 8762-6.
- Drake, D. R., 3rd, Moser, J. M., Hadley, A., Altman, J. D., Maliszewski, C., Butz, E. & Lukacher, A. E. (2000). "Polyomavirus-Infected Dendritic Cells Induce Antiviral CD8(+) T Lymphocytes." *J. Virol.*, 74, 4093-4101.
- Tan, J. T., Whitmire, J. K., Murali-Krishna, K., Ahmed, R., Altman, J. D., Mittler, R. S., Sette, A., Pearson, T. C. & Larsen, C. P. (2000). "4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination." *J. Immunol.*, 164, 2320-5.
- Gray, C. M., Lawrence, J., Ranheim, E. A., Vierra, M., Zupancic, M., Winters, M., Altman, J., Montoya, J., Zolopa, A., Schapiro, J., Haase, A. T. & Merigan, T. C. (2000). "Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells ." *AIDS Res. Hum. Retroviruses*, 16, 1357-69.
- Gea-Banacloche, J. C., Migueles, S. A., Martino, L., Shupert, W. L., McNeil, A. C., Sabbaghian, M. S., Ehler, L., Prussin, C., Stevens, R., Lambert, L., Altman, J., Hallahan, C. W., de Quiros, J. C. & Connors, M. (2000). "Maintenance of large numbers of virus-specific CD8+ T cells in HIV- infected progressors and long-term nonprogressors." *J. Immunol.*, 165, 1082-92.
- Allen, T. M., O'Connor, D. H., Jing, P., Dzuris, J. L., Mothe, B. R., Vogel, T. U., Dunphy, E., Liebl, M. E., Emerson, C., Wilson, N., Kunstman, K. J., Wang, X., Allison, D. B., Hughes, A. L., Desrosiers, R. C., Altman, J. D., Wolinsky, S. M., Sette, A. & Watkins, D. I. (2000). "Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia." *Nature*, 407, 3 86-390.
- Hel, Z., Venzon, D., Poudyal, M., Tsai, W. P., Giuliani, L., Woodward, R., Chouquet, C., Shearer, G., Altman, J. D., Watkins, D., Bischofberger, N., Abimiku, A., Markham, P., Tartaglia, J. & Franchini, G. (2000). "Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV25 1 infection of macaques." *Nat. Med.*, 6, 1140-6.
- Allen, T. M., Vogel, T. U., Fuller, D. H., Mothe, B. R., Steffen, S., Boyson, J. E., Shipley, T., Fuller, J., Hanke, T., Sette, A., Altman, J. D., Moss, B., McMichael, A. J. & Watkins, D. I. (2000). "Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA Prime/Modified vaccinia virus ankara boost regimen." *J. Immunol.*, 164, 4968-78.
- Huang, C. C., Coppola, M. A., Nguyen, P., Carragher, D., Rohl, C., Flynn, K. J., Altman,

- J. D. & Blackman, M. A. (2000). "Effect of *Staphylococcus Enterotoxin B* on the Concurrent CD8(+) T Cell Response to Influenza Virus Infection." *Cell. Immunol.*, 204, 1-10.
- Burrows, S. R., Kienzle, N., Winterhalter, A., Bharadwaj, M., Altman, J. D. & Brooks, A. (2000). "Peptide-MHC Class I Tetrameric Complexes Display Exquisite Ligand Specificity." *J. Immunol.*, 165, 6229-6234.
- Hel, Z., Nacsá, J., Kelsall, B., Tsai, W. P., Letvin, N., Parks, R. W., Tryniszewska, E., Picker, L., Lewis, M. G., Edghill-Smith, Y., Moniuszko, M., Pal, R., Stevceva, L., Altman, J. D., Allen, T. M., Watkins, D., Torres, J. V., Berzofsky, J. A., Belyakov, I. M., Strober, W. & Franchini, G. (2001). "Impairment of Gag-Specific CD8(+) T-Cell Function in Mucosal and Systemic Compartments of Simian Immunodeficiency Virus mac251- and Simian-Human Immunodeficiency Virus KU2-Infected Macaques." *J. Virol.*, 75, 11483-95.
- Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G., Wyatt, L. S., Candido, M. A., Kozyr, N. L., Earl, P. L., Smith, J. M., Ma, H. L., Grimm, B. D., Hulsey, M. L., Miller, J., McClure, H. M., McNicholl, J. M., Moss, B. & Robinson, H. L. (2001). "Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine." *Science*, 292, 69-74.
- Allen, T. M., Mothe, B. R., Sidney, J., Jing, P., Dzuris, J. L., Liebl, M. E., Vogel, T. U., O'Connor, D. H., Wang, X., Wussow, M. C., Thomson, J. A., Altman, J. D., Watkins, D. I. & Sette, A. (2001). "CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing." *J. Virol.*, 75, 73 8-49.
- Moser, J. M., Altman, J. D. & Lukacher, A. E. (2001). "Antiviral CD8+ T cell responses in neonatal mice: susceptibility to polyoma virus-induced tumors is associated with lack of cytotoxic function by viral antigen-specific T cells." *J. Exp. Med.*, 193, 595-606.
- Grayson, J. M., Murali-Krishna, K., Altman, J. D. & Ahmed, R. (2001). "Gene expression in antigen-specific CD8+ T cells during viral infection." *J. Immunol.*, 166, 795-9.
- Xiong, Y., Luscher, M. A., Altman, J. D., Hulsey, M., Robinson, H. L., Ostrowski, M., Barber, B. H. & MacDonald, K. S. (2001). "Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation." *J. Virol.*, 75, 3028-3 3.
- Sherritt, M., Cooper, L., Moss, D. J., Kienzle, N., Altman, J. & Khanna, R. (2001). "Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters." *Int. Immunol.*, 13, 265-71.
- Puglielli, M. T., Zajac, A. J., van der Most, R. G., Dzuris, J. L., Sette, A., Altman, J. D. & Ahmed, R. (2001). "In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb." *J. Virol.*, 75, 5099-107.
- Bond, K. B., Sriwanthana, B., Hodge, T. W., De Groot, A. S., Mastro, T. D., Young, N. L., Promadej, N., Altman, J. D., Limpakarnjanarat, K. & McNicholl, J. M. (2001). "An HLA-directed molecular and bioinformatics approach identifies new HLA-A1 1 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1- infected Thais." *AIDS Res. Hum. Retroviruses*, 17, 703-17.
- Vogel, T. U., Allen, T. M., Altman, J. D. & Watkins, D. I. (2001). "Functional impairment of

- simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection.” *J. Virol.*, 75, 2458-61.
- Veazey, R. S., Gauduin, M. C., Mansfield, K. G., Tham, I. C., Altman, J. D., Lifson, J. D., Lackner, A. A. & Johnson, R. P. (2001). “Emergence and kinetics of simian immunodeficiency virus-specific CD8(+) T cells in the intestines of macaques during primary infection.” *J. Virol.*, 75, 105 15-9.
- Grayson, J. M., Lanier, J. G., Altman, J. D. & Ahmed, R. (2001). “The Role of p53 in Regulating Antiviral T Cell Responses.” *J. Immunol.*, 167, 1333-7.
- Suresh, M., Whitmire, J. K., Harrington, L. E., Larsen, C. P., Pearson, T. C., Altman, J. D. & Ahmed, R. (2001). “Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory.” *J. Immunol.*, 167, 5565-73.
- Belyakov, I. M., Hel, Z., Kelsall, B., Kuznetsov, V. A., Ahlers, J. D., Nacsá, J., Watkins, D. I., Allen, T. M., Sette, A., Altman, J., Woodward, R., Markham, P. D., Clements, J. D., Franchini, G., Strober, W. & Berzofsky, J. A. (2001). “Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.” *Nat Med*, 7, 1320-6.
- Daniels, M. A., Miller, J. D., Moser, J. M., Devine, L., Kavathas, P. B., Lukacher, A. E., Altman, J. D., Hogquist, K. A. & Jameson, S. C. (2001). “CD8 binding to MHC Class I molecules is influenced by T cell maturation and glycosylation.” *Immunity*. 15, 105 1-61.
- Blattman, J.N., Antia, R., Sourdive, D.J.D., Wang, X., Kaech, S., Murali-Krishna, K., Altman, J.D., and Ahmed, R. (2002). “Estimating the precursor frequency of naive antigen specific CD8 T cells” *J. Exp. Med.* 195, 657-64.
- Miller, J.D., Peters, M., Oran, A.E., Beresford, G.W., Harrington, L., Boss, J.M., and Altman, J.D. (2002). “CD94/NKG2 Expression does not inhibit virus-specific cytotoxic function of lymphocytic choriomeningitis virus-specific CD8+ T cells.” *J. Immunol.*, 169, 693-701.
- Allen, T.M., Mortara, L., Mothe, B. R., Liebl, M., Jing, P., Calore, B., Piekarczyk, M., Ruddersdorf, R., O’Connor, D. H., Wang, X., Wang, C., Allison, D. B., Altman, J. D., Sette, A., Desrosiers, R. C., Sutter, G. & Watkins, D. I. (2002). “Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.” *J Virol*, 76, 4108-12.
- Amara, R. R., Smith, J. M., Staprans, S. I., Montefiori, D. C., Villinger, F., Altman, J. D., O’Neil, S. P., Kozyr, N. L., Xu, Y., Wyatt, L. S., Earl, P. L., Herndon, J. G., McNicholl, J. M., McClure, H. M., Moss, B. & Robinson, H. L. (2002). “Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.” *J Virol*, 76, 6138-46.
- Amara, R.R., Villanger, F., Altman, J.D., Lydy, S.L., O’Neil, S.P., Staprans, S.I., Montefiori, D.C., Xu., Y., Herndon, J.G., Wyatt, L.S., Candido, M.A., Kozyr, N.L., McNicholl, J.M., Moss,s B. & Robinson, H.L. (2002) “Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.” *Vaccine*, 20, 1949-55.
- Amara, R. R., Villinger, F., Staprans, S. I., Altman, J. D., Montefiori, D. C., Kozyr, N. L., Xu, Y., Wyatt, L. S., Earl, P. L., Herndon, J. G., McClure, H. M., Moss, B. & Robinson, H. L. (2002). “Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNAMVA vaccines.” *J Virol*, 76, 7625-31.
- Ansari, A.A., Mayne, A. E., Sundstrom, J. B., Bostik, P., Grimm, B., Altman, J. D. & Villinger, F. (2002). “Administration of recombinant rhesus interleukin-12 during acute simian

- immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac25 1-infected rhesus macaques.” *J Virol*, 76, 173 1-43.
- Halsted, E. S., Mueller, Y. M., Altman, J. D. & Katsikis, P. D. (2002). “In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses.” *Nat Immunol*, 3, 536-41.
- Huang, C. C., Shah, S., Nguyen, P., Altman, J. D. & Blackman, M. A. (2002). “Bacterial superantigen exposure after resolution of influenza virus infection perturbs the virus-specific memory CD8(+)T-cell repertoire.” *J Virol*, 76, 6852-6.
- Liu, L., Chahroudi, A., Silvestri, G., Wernett, M. E., Kaiser, W. J., Safrit, J. T., Komoriya, A., Altman, J. D., Packard, B. Z. & Feinberg, M. B. (2002). “Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates.” *Nat Med*, 8, 185-9.
- Mothe, B.R., Horton, H., Carter, D. K., Allen, T. M., Liebl, M. E., Skinner, P., Vogel, T. U., Fuenger, S., Vielhuber, K., Rehrauer, W., Wilson, N., Franchini, G., Altman, J. D., Haase, A., Picker, L. J., Allison, D. B. & Watkins, D. I. (2002). “Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.” *J Virol*, 76, 875-84.
- Suresh, M., Lanier, G., Large, M. K., Whitmire, J. K., Altman, J. D., Ruddle, N. H. & Ahmed, R. (2002). “Role of lymphotoxin alpha in T-cell responses during an acute viral infection.” *J Virol*, 76, 3943-5 1.
- Hel, Z., Tryniszewska, E., Tsai, W. P., Johnson, J. M., Harrod, R., Fullen, J., Kalyanaraman, V. S., Altman J. D., McNally, J., Karpova, T., Felber, B. K., Tartaglia, J., Franchini, G. (2002) “Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes.” *DNA & Cell Biol*, 21, 619-26.
- Allen, T. M., Jing, P., Calore, B., Horton, H., O’Connor, D. H., Hanke, T., Piekarczyk, M., Ruddersdorf, R., Mothe, B. R., Emerson, C., Wilson, N., Lifson, J. D., Belyakov, I. M., Berzofsky, J. A., Wang, C., Allison, D. B., Montefiori, D. C., Desrosiers R. C., Wolinsky, S., Kunstman, K. , Altman, J. D., Sette, A., McMichael, A. J., Watkins, D. I. (2002) “Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.” *J Virol*, 76, 10507-11.
- Mueller, Y. M., Bojczuk, P. M., Halstead, E. S., Kim, A.H., Witek, J., Altman, J. D., Katsikis, P. D.: (2003) “IL-15 enhances survival and function of HIV-specific CD8+ T cells.” *Blood*, 101, 1024-9.
- Vogel, T. U., Beer, B. E., zur Megede, J., Ihlenfeldt, H. G., Jung, G., Holzammer, S., Watkins, D. I., Altman, J. D., Kurth, R., Norley, S. (2002) “Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity nd reduction of cell-associated but not plasma virus load following challenge.” *J Gen Virol*, 83, 81-91.
- Constantin, C. M., Bonney, E. E., Altman, J. D., Strickland, O.L. (2002) “Major histocompatibility complex (MHC) tetramer technology: an evaluation.” *Biological Research for Nursing*, 4, 115-27.
- Ravkov, E., Myrick, C. M. & Altman, J. D. (2003). “Immediate Early Effector Functions of Virus-Specific CD8+CCR7+ Memory Cells in Humans Defined by HLA and CC Chemokins Ligand 19 Tetramers.” *J. Immunol.*, 170, 2461-2468.
- Wang, X. & Altman, J. D. (2003). “Design of MHC Class I Tetramer / Antigen-Specific T

- Lymphocyte Dissociation Assays.” *J Immunol Methods*, 280, 25-35
- Jamieson, B.D., Yang, O.O., Hultin, L., Hausner, M.A., Hultin, P., Matud, J., Kunstman, K., Killian, S., Altman, J., Kommander, K., Korber, B., Giorgi, J., Wolinsky, S. (2003) “Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1- Specific CTL Responses.” *J. Immunol.*, 171, 5372-5379.
- Altman, J.D. & Feinberg, M.B. (2004) “HIV Escape: There and Back Again” *Nature Medicine*, 10, 229-230
- Altman, J.D. (2004) “Flow cytometry applications of MHC tetramers.” *Methods Cell Biol.*, 75, 43 3-52.
- Garber, D.A., Silvestri, G., Barry, A.P., Fedanov, A., Kozyr, N., McClure, H., Montefiori, D.C., Larsen, C.P., Altman, J.D., Staprans, S.I., Feinberg, M.B. (2004) Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication.” *J Clin Invest.*, 113, 83 6-45.
- Petrovas, C., Mueller, Y.M., Dimitriou, I.D., Bojczuk, P.M., Mounzer, K.C., Witek, J., Altman, J.D., Katsikis, P.D. (2004) “HIV-specific CD8+ T cells exhibit markedly reduced levels of Bcl-2 and Bcl-xL.” *Immunol.* 172, 4444-53.
- Paiardini, M., Cervasi, B., Albrecht, H., Muthukumar, A., Dunham, R., Gordon, S., Radziewicz, H., Weintrob, A., Montroni, M., Kaech, S. M., Altman, J. D., Sodora, D. L., Feinberg, M. B. and Silvestri, G. (in press) “Loss of CD127 (interleukin-7 receptor) defines an expansion of CD8+ effector T cells in HIV-infected patients” *J. Immunol.*, 174:2900-9.
- McHeyzer-Williams, M. G., Altman, J. D. & Davis, M. M. (1996). “Enumeration and characterization of memory cells in the TH compartment.” *Immunol. Rev.*, 150, 5-21.
- McHeyzer-Williams, M. G., Altman, J. D. & Davis, M. M. (1996). “Tracking antigen-specific helper T cell responses.” *Curr. Opin. Immunol.* , 8, 278-284. Davis, M. M., Lyons, D. S., Altman, J. D., McHeyzer-Williams, M., Hampl, J., Boniface, J. J. & Chien, Y. (1997). “T cell receptor biochemistry, repertoire selection and general features of TCR and Ig structure.” *Ciba Found. Symp.*, 204, 94-100; discussion 100-4.
- Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D., Zajac, A. & Ahmed, R. (1998). “In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection.” *Adv. Exp. Med. Biol.*, 452, 123-42.
- Altman, J. D. & Safrit, J. T. (1998) “MHC Tetramer Analyses of CD8+ T Cell Responses to HIV and SIV.” in *HIV Molecular Immunology Database 1998*. (Korber, B., Brander, C., Haynes, B., Koup, R., Moore, J. & B., W., eds.) Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, pp. IV-36-45.
- Altman, J. D. & Lippolis, J. D. (2001) “Cytotoxic T-cell function.” in *Clinical Immunology*. (Rich, R. R., Fleisher, T. A., Shearer, W. T., Kotzin, B. L. & Schroeder, H. W., Jr., eds.) Harcourt, London, pp. 17.1-17.9.
- Altman, J. D. (2004) “Flow Cytometry Application of MHC Tetramers” in *Methods In Cell Biology*. (Darzynkiewicz, Z., Roederer, M. and Tanke, H. J., eds.) Academic Press, New York, 75 :433-452.

ABSTRACT

John D. Altman was born and raised in Birmingham, a suburb of Detroit, Michigan. He and his sister, two years younger, attended public schools, where, without parental prodding (or so he remembers), both were good students. He had an inspiring literature class in high school but remembers no inspirational classes in the sciences. His family belonged to a Hebrewless temple where the rabbi had established the Society for Humanistic Judaism; Altman was bar mitzvah there in an unusual ceremony.

Altman had planned to attend medical school after obtaining an electrical engineering degree at Massachusetts Institute of Technology, after which he would work on medically related things, but by what he calls incremental steps he reverted to biology. Soon after beginning college he switched majors to chemistry, working in Michael Marletta's toxicology laboratory throughout his college career. Extracurricular activities included fishing in Gloucester, biking, and playing intramural hockey on his fraternity's team.

During his junior year he realized that he wanted to go into research, not medicine, and he decided to attend the University of California, San Francisco, for graduate school; his two influences for this decision were Marletta and Gregory Petsko. At the University of California, San Francisco, his doctoral research in Irwin Kuntz's biophysical chemistry laboratory involved using two-dimensional nuclear magnetic resonance spectroscopy to study protein structure.

Altman then discusses his experiences and project with Steve Anderson at Genentech Corporation during his postdoctoral fellowship in Mark Davis's immunology laboratory at Stanford University. At Stanford he meets and marries his wife. Altman continues with a discussion of his postdoctoral research on protein chemistry and immunology with T cells in the Davis laboratory; his collaborations with Oxford University studying T cells and HIV immunity; his defining moment at Oxford; and meeting Rafi Ahmed.

Altman accepted a position at the Vaccine Center of Emory University and set up his lab. Altman then delves into his funding history. He explains his administrative roles at the Emory Vaccine Center and the MHC Tetramer Core Facility; he talks about his collaborations, his current research in viral immunology, and his direction of the Immunology Core Laboratory in the Vaccine Center. He explains the funding at the MHC Tetramer Core Facility and discusses his patent and his research on vaccines at the Southeastern Regional Center for Excellence in Biodefense.

Altman describes his lab management style and the makeup of his lab and discusses how he would like to set the national science agenda. He concludes the interview by reflecting upon the wider context of his work, the impact of the Pew Scholars Program in the Biomedical Sciences grant on his work, the grant-writing process, and the issues of patents, politics, religion, and ethical questions in science.

UCLA INTERVIEW HISTORY

INTERVIEWER:

Karen A. Frenkel, Interviewer, UCLA Oral History Program; B.A., Hampshire College, 1978; M.S., Boston University, 1982

TIME AND SETTING OF INTERVIEW:

Place: John Altman's office at Emory Vaccine Center in the Yerkes Regional Primate Center, Emory University, Atlanta, GA.

Date: January 30, 31, and February 1, 2006.

Total number of recorded hours: 6

Persons present during interview: Altman and Frenkel.

CONDUCT OF INTERVIEW:

This interview is one in a series with Pew Scholars in the Biomedical Sciences conducted by the UCLA Oral History Program in conjunction with the Pew Charitable Trusts' Pew Scholars in the Biomedical Sciences Oral History and Archives Project. The project has been designed to document the backgrounds, education, and research of biomedical scientists awarded four-year Pew scholarships since 1988.

To provide an overall framework for project interviews, the director of the UCLA Oral History Program and three UCLA faculty project consultants developed a topic outline. In preparing for this interview, Frenkel held a telephone pre-interview conversation with Altman to obtain written background information (curriculum vitae, copies of published articles, etc.) and agree on an interviewing schedule. She also reviewed the documentation in Altman's file at the Pew Scholars Program office in San Francisco, including his proposal application, letters of recommendation, and reviews by Pew Scholars Program national advisory committee members.

ORIGINAL EDITING:

Carol Squires edited the interview. She checked the verbatim transcript of the interview against the original tape recordings, edited for punctuation, paragraphing, and spelling, and verified proper names. Words and phrases inserted by the editor have been bracketed.

Altman did not review the transcript. Consequently, some proper names and other information remain unverified.

TABLE OF CONTENTS

Childhood, College, and Starting Graduate School	1
Childhood interests and experiences. Attending school in Birmingham, Michigan.	
Career path in science. Family background. Parental expectations. Sister.	
Religion. Interest in literature. Attends Massachusetts Institute of Technology.	
Decision to major in chemistry instead of engineering. Works in Michael A.	
Marletta's toxicology laboratory during college. Marletta's mentoring style.	
Extracurricular activities in college. College experiences. Decision to pursue a career in scientific research. Attends graduate school in pharmaceutical chemistry at University of California, San Francisco. Works in Irwin D. Kuntz's biophysical chemistry laboratory.	
Graduate School, Postdoctoral Research, and Setting Up a Lab at Emory University	30
Doctoral research in Kuntz's laboratory using two-dimensional nuclear magnetic resonance spectroscopy to study protein structure. Kuntz laboratory. Project and training with Steve Anderson at Genentech Corporation. Experiences at Genentech Corporation during graduate school. Postdoctoral fellowship in Mark Davis's immunology laboratory at Stanford University. Meets and marries wife.	
Importance of peer interactions in science. Davis's mentoring style.	
Postdoctoral research on protein chemistry and immunology with T cells.	
Collaborations at Oxford University studying T cells and HIV immunity. Defining moment at Oxford. Meets Rafi Ahmed. Accepts a position at the Vaccine Center of Emory University. Setting up his lab. Funding history.	
Work at Emory and Reflections on Science	63
Administrative roles at the Emory Vaccine Center and the MHC Tetramer Core Facility. Collaborations. Current research in viral immunology. The MHC Tetramer Core Facility. Direction of the Immunology Core Laboratory in the Vaccine Center. Funding the MHC Tetramer Core Facility. Patent. National science agenda. Research on vaccines at the Southeastern Regional Center for Excellence in Biodefense. Lab management style. Pew Scholars Program in the Biomedical Sciences. Grant-writing process. Writing. Politics, religion, and science. Ethical questions in science. Educating the public about science. Professional goals. Ethnic and gender issues in science.	
Index	109

INDEX

A

acquired immunodeficiency syndrome, 44, 70, 72, 78, 81, 82, 83, 84, 100, 101, 104, 105
Affymax, 55
Affymetrix, 55
Africa, 81, 100
Ahmed, Rafi, 59, 60, 63, 64, 68, 73, 76, 88, 92, 105
AIDS. *See* acquired immunodeficiency syndrome
Alighieri, Dante, 11
Altman, Eve (daughter), 62
Altman, Jacob (son), 60
Altman, Leslie (wife), 46, 48, 57, 60, 62
American Cancer Society, 43, 44, 74
Anderson, Steven M., 35, 38, 41
Ann Arbor, Michigan, 12
anthrax, 65, 82, 84, 90
Arab, 5
Argentina, 85
Arrowsmith, 11
Atlanta, Georgia, 38, 60, 62, 74, 80, 89
Australia, 53, 81

B

Barouck, Daniel, 56
B-cell, 17, 53
Beckman Corporation, 78
Beckman-Coulter Corporation, 78
Bell, John, 55
biodefense, 75, 82, 85, 90
biotin, 55
Birmingham Temple, 6
Birmingham, Michigan, 1
Boston, Massachusetts, 13, 21, 22, 24, 46, 48, 78, 88, 89
Botswana, 81
Brandeis University, 29
Brazil, 81
Bush, President George W., 90, 100

C

California Institute of Technology, 14
Canton, China, 61
CDC. *See* Centers for Disease Control
Center for AIDS Research, 65, 72, 73
Centers for Disease Control, 65, 74, 82, 102, 103
CFAR. *See* Center for AIDS Research
Charles River, 13, 17
China, 60, 61, 62, 82
chromatography, 63, 70
collaboration, 30, 34, 41, 51, 52, 53, 55, 57, 63, 66, 68, 69, 72, 85, 91
Computer Graphics Laboratory, 46
Costa Rica, 47, 85, 88
Coulter Corporation, 78
Cronkite, Walter, 10
crystallography, 31, 33, 42
cytochrome P450, 16, 17

D

Davis, Mark, 42, 43, 45, 47, 50, 51, 52, 55, 57, 59, 76, 78, 89
Davos, Switzerland, 9
dengue virus, 85, 88
Detroit, Michigan, 1, 2, 4, 5, 6, 9, 13
deuterium, 34, 35
DNA, 27, 78
Doherty, Peter C., 50, 68, 69
Dostoevsky, Fyodor, 11
Driscoll, Paul, 51
Duke University, 81, 82

E

E. coli, 34, 51, 52, 55
East Africa, 7
Ebola, 90
Emory Center for AIDS Research, 71
Emory University, 38, 59, 66, 72, 73, 74, 77, 82, 86, 88, 89, 92, 98, 99, 105

First Program, 86
Emory Vaccine Center, 38, 59, 60, 65, 71, 105
enzymology, 26, 27, 28, 30
Ethical Culture, 6
ethics, 39, 101, 102
Ethiopia, 81
Europe, 5, 81

F

Faust, 11
Ferrari, Guido, 81
flow cytometer, 53, 56, 63, 64, 71, 72, 89
Frank, Representative Barney, 25

G

Gambia, 81
Genbank, 46
gender, 106
Genentech Inc., 34, 38, 41
Georgia Research Alliance, 64
Germany, 81
Glaxco Smith-Kline, 101
GRA. *See* Georgia Research Alliance
grants/funding, 31, 44, 46, 49, 62, 63, 65, 67, 69, 71, 75, 77, 82, 83, 88, 90, 91, 92, 93, 94, 98, 102, 103, 105
Gray, Clive, 58, 81
Great Britain, 18, 51
Guangzhou, China, 61

H

Hafler, David, 78
Harvard University, 18, 19, 29, 30, 56
Hebrew, 7, 8
herpes viruses, 86
HIV. *See* human immunodeficiency virus
Hong Kong, 61
Human Genome Project, 83
human immunodeficiency virus, 55, 56, 57, 58, 63, 66, 72, 74, 78, 79, 84, 88, 105, 107

I

Ibegbu, Chris, 72

immunology, 40, 42, 43, 53, 57, 58, 63, 65, 68, 71, 72, 79, 85, 90
Immunology Core Laboratory, 71, 73
India, 81, 82
influenza, 74, 83, 85, 90, 105
Isle of Wight, 56
Italy, 81

J

Jews/Jewish/Judaism, 6, 102
Johannesburg, South Africa, 58, 81
Joyce, James, 11

K

Kent State University, 10
Kerry, Senator John, 9
Keystone Symposia, 68
Korea, 61
Kossiakoff, Anthony, 38, 41, 42
Kreb's Cycle, 27
Kuntz, Irwin "Tack", 30, 31, 32, 34, 41

L

Lanier, Mary, 88
London, England, 52
Long, Roy M., 59

M

Madison, Wisconsin, 30
major histocompatibility complex, 42, 43, 51, 52, 53, 54, 55, 56, 63, 66, 67, 69, 70, 71, 72, 77, 78, 79, 97, 99
class 1, 42, 56
class 2, 42, 43, 52
Marletta, Michael A., 16, 18, 24, 25, 27, 28, 29, 30
Marxism, 8
Massachusetts General Hospital, 46
Massachusetts Institute of Technology, 2, 9, 12, 14, 16, 18, 20, 21, 24, 26, 37, 42, 45
Undergraduate Research Opportunities Program, 16
McHeyzer-Williams, Michael, 53, 54, 55, 72, 78

McMichael, Andrew, 55, 56, 59, 63, 78
measles, 74, 88
Medical College of Wisconsin, 59
Mein Kampf, 8
Memphis, Tennessee, 68, 69, 86
Merck & Co., Inc., 101, 102
Merriman, Tom, 58
MHC. *See* major histocompatibility complex
MHC Tetramer Core Facility, 65, 69, 79
Miami, Florida, 78
Miller, Governor Zell, 64
minorities, 107
MIT. *See* Massachusetts Institute of Technology
Mooney, Christopher C., 100
Moss, Paul, 56, 57

N

National Hockey League, 24
National Institute of Allergy and Infectious Diseases, 78
National Institutes of Health, 63, 64, 65, 66, 69, 70, 77, 78, 79, 82, 91, 98, 102, 103
New York City, New York, 6
Newport Beach, California, 5
Nigeria, 81
NIH. *See* National Institutes of Health
Nilsson, Bjorn, 34, 35
NMR. *See* nuclear magnetic resonance
Nobel Prize, 2, 68
nuclear magnetic resonance, 31, 32, 35, 51

O

Oak Park, Michigan, 4
Olympic Games, 60

P

Palo Alto, California, 61
papilloma, 101, 102
 HPV 16, 101
 HPV 18, 101
paramagnetic spin label, 32, 34
Paris, France, 69

patent, 58, 77, 78, 97, 98, 99
Petsco, Gregory, 18, 30
Pew Charitable Trusts, 85
Pew Scholars Program in the Biomedical Sciences, 1, 11, 40, 76, 80, 91
Princeton University, 46

R

Rand, Ayn, 8
Reagan, President Ronald W., 21, 25
religion, 6, 102
 Jews/Jewish/Judaism, 4, 6, 7, 21
 bar mitzvah, 7
 barocha, 7
 Torah, 7
Republican War on Science, 100
RNA
 tRNA, 40
Russell, Bertrand, 8
Russia, 82

S

Sabin, Albert, 99
Salk, Jonas, 99
San Carlos, California, 49
San Francisco, California, 36, 48, 58, 88
SARS, 90
Seoul, South Korea, 61
September 11, 2001, 71, 74, 82, 90
Sharpless, K. Barry, 2
Shotts, Peter, 55
smallpox, 82, 83, 84
Society for Humanistic Judaism, 6
South Africa, 58, 69, 81, 101
South America, 61
Southeast Regional Center of Excellence in Biodefense, 65, 66, 71, 72, 82, 83, 84, 106
spectroscopy, 31, 32, 35, 51
 2-D nuclear magnetic resonance, 31
St. Jude Children's Research Hospital, 68, 69
Stanford University, 42, 48, 49, 57, 58, 59, 60, 72, 76, 77, 78, 98, 99
scriptabodin, 55
synchrotron, 33

T

- T-cell, 28, 42, 43, 44, 52, 53, 54, 55, 56, 57, 59, 66, 67, 71, 86, 88
tenure, 18
Thailand, 82
Tolkein, J.R.R., 19
tularemia, 84

U

- U.S. Food and Drug Administration, 101
UCLA. *See* University of California, Los Angeles
UCSF. *See* University of California, San Francisco
Uganda, 7
United States of America, 57, 69
University of Alabama, 82
University of California, Berkeley, 36
University of California, Davis, 88
University of California, Los Angeles, 59
University of California, San Diego, 29
University of California, San Francisco, 18, 19, 29, 30, 35, 36, 38, 39, 42, 45, 46, 47, 48, 49
University of Florida, 82
University of Michigan, 12
University of North Carolina, 82
University of Oxford, 18, 52, 55, 56, 58, 59, 78

- University of Tennessee, 86
University of Wisconsin, 29

V

- vaccinia, 84
Vanderbilt University, 82
varicella zoster virus, 66, 91
vesicular stomatitis virus, 84, 85
Vietnam War, 10
Virginia, 70
virology, 85, 86, 89

W

- Watergate, 10
Wein, Sherwin, 6
Wells, James, 38, 41, 42
West Nile virus, 83
World Economic Forum, 9

Y

- Yale University, 42
Yerkes National Primate Research Center, 73, 107

Z

- Zangwill, Israel, 7
Zionism/Zionist, 7
Zoller, Martin, 38